Healthcare & Medical Devices India On demand · 24-48h

India Point-of-Care Testing Devices and In-Vitro Diagnostics Market Strategic Research Report

India Point-of-Care Testing Devices and In-Vitro Diagnostics…
$1,195 USD
Market Research Reports
Strategic Research Report
India Point-of-Care Testing Devices and In-Vitro Diagnostics Market
$3.2B2025
9.8%CAGR
2032Forecast
Market Research Reports · India
Market Research Reports Intelligence Series

By Type: Rapid Diagnostic Tests, Molecular Diagnostics, Glucose Monitoring

By Application: Immunoassay Analysers, Infectious Disease Testing, Diabetes & Cardiac PoC

Regional Forecast: South India, North India, West India, East India, Central India

Key Players: Abbott India Limited, Siemens Healthineers India, Roche Diagnostics India, Becton Dickinson India (BD India), bioMérieux India, Tulip Diagnostics (P) Ltd, J. Mitra & Co. Pvt. Ltd., Transasia Bio-Medicals Ltd, Mylab Discovery Solutions Pvt. Ltd., Meril Diagnostics Pvt. Ltd.

Region: India
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Market size 2025
$3.2B
Billion USD
Forecast CAGR
9.8%
2025-2032
Forecast 2032
$6.2B
Projected
Régions
5
South India · North India · West India · East India · Central India

Vue d'ensemble

India's Point-of-Care (PoC) Testing Devices and In-Vitro Diagnostics (IVD) market stood at approximately USD 3.2 billion in 2024, positioning the country among the fastest-growing diagnostic markets in the Asia-Pacific region. The market encompasses a wide spectrum of diagnostic technologies—from rapid antigen tests and glucose monitoring devices to molecular diagnostics and immunoassay analyzers—deployed across hospitals, independent diagnostic laboratories, primary health centres, and home care settings. India's vast disease burden, which includes the world's largest tuberculosis caseload, a diabetic population exceeding 100 million, and surging demand for infectious disease surveillance, creates a structurally high requirement for accessible and affordable diagnostic solutions. The shift from centralised laboratory testing toward point-of-care delivery is accelerating as healthcare infrastructure expands into tier-2 and tier-3 cities, validating the strategic importance of this market for both domestic manufacturers and multinational diagnostics companies.

Market snapshot

India Point-of-Care Testing Devices and In-Vitro Diagnostics Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 9.8%
Regional growth momentum
Market share by segment
Key metrics
Base value
$3.2B
2025
Forecast
$6.2B
2032
Volume
4500
Million Dosage Units, 2025
Volume 2032
8658.2
Million Dosage Units
Key companies
Abbott India LimitedSiemens Healthineers IndiaRoche Diagnostics IndiaBecton Dickinson India (BD India)bioMérieux IndiaTulip Diagnostics (P) LtdJ. Mitra & Co. Pvt. Ltd.Transasia Bio-Medicals Ltd
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Rapid Diagnostic TestsMolecular DiagnosticsGlucose Monitoring
By Application
Immunoassay AnalysersInfectious Disease TestingDiabetes & Cardiac PoC

Table of contents

Click a chapter to expand
01Executive Summary
  • 1.1 Market Synopsis
  • 1.2 Key Findings
  • 1.3 Strategic Recommendations
02Industry Overview & Forecast
  • 2.1 Market Definition & Scope
  • 2.2 Market Value & Volume Forecast (Million Dosage Units), 2025-2032
  • 2.3 CAGR Analysis & Confidence Intervals
  • 2.4 Historical Market Review, 2019-2024
  • 2.5 Scenario Analysis (Base, Bull, Bear Cases)
03Market Segmentation by Type
  • 3.1 Market by Type Overview
  • 3.2 Rapid Diagnostic Tests (RDTs) — Lateral Flow Assays (Value & Volume)
  • 3.3 Molecular Diagnostics — PCR, NAAT & Isothermal Amplification Devices (Value & Volume)
  • 3.4 Glucose Monitoring Devices — SMBG & Continuous Glucose Monitors (Value & Volume)
  • 3.5 Immunoassay Analysers & Reagent Kits (Value & Volume)
  • 3.6 Haematology & Coagulation Analysers (Value & Volume)
  • 3.7 Urinalysis & Clinical Chemistry PoC Strips and Devices (Value & Volume)
04Market Segmentation by Application
  • 4.1 Market by Application Overview
  • 4.2 Infectious Disease Diagnostics — Tuberculosis, Malaria, Dengue, HIV, COVID-19 (Value & Volume)
  • 4.3 Diabetes Monitoring & Glycated Haemoglobin (HbA1c) Testing (Value & Volume)
  • 4.4 Cardiac Markers & Acute Care Diagnostics (Value & Volume)
  • 4.5 Women's Health — Pregnancy, Fertility & Maternal Screening (Value & Volume)
  • 4.6 Oncology & Tumour Marker Testing (Value & Volume)
  • 4.7 Drug-of-Abuse and Forensic Testing (Value & Volume)
05Regional Market Forecast
  • 5.1 Regional Revenue Share & CAGR within India (2024 vs 2032)
  • 5.2 South India (Value & Volume)
  • 5.3 North India (Value & Volume)
  • 5.4 West India (Value & Volume)
  • 5.5 East India (Value & Volume)
  • 5.6 Central India (Value & Volume)
06State-Level Market Forecast
  • 6.1 Key States Overview — Diagnostic Infrastructure & Market Penetration
  • 6.2 Maharashtra — Private Hospital Networks, Diagnostic Chains & Urban PoC Adoption
  • 6.3 Karnataka — Medtech Manufacturing Hub & Bengaluru Diagnostics Ecosystem
  • 6.4 Tamil Nadu — Government Health Mission & Tier-2 City IVD Expansion
  • 6.5 Gujarat — Pharmaceutical Supply Chain Integration & Surat/Ahmedabad Lab Networks
  • 6.6 Uttar Pradesh — High Disease Burden, Ayushman Bharat Penetration & Rural PoC Demand
  • 6.7 Delhi NCR — Corporate Hospital Clusters, Import Hubs & Premium IVD Adoption
07Growth Drivers & Inhibitors
  • 7.1 Ayushman Bharat — Pradhan Mantri Jan Arogya Yojana (PM-JAY) Driving Diagnostic Access for 500 Million Beneficiaries
  • 7.2 National Tuberculosis Elimination Programme (NTEP) Mandating Molecular PoC Testing at District Level
  • 7.3 Rising Prevalence of Non-Communicable Diseases — Diabetes, Hypertension & Cardiovascular Conditions Expanding Chronic-Disease IVD Demand
  • 7.4 Market Restraints & Challenges
  • 7.5 Opportunities & White-Space Analysis
08Key Company Profiles
  • 8.1 Abbott India Limited — Revenue, Strategy, Key Products
  • 8.2 Siemens Healthineers India — Revenue, Strategy, Key Products
  • 8.3 Roche Diagnostics India — Revenue, Strategy, Key Products
  • 8.4 Becton Dickinson India (BD India) — Revenue, Strategy, Key Products
  • 8.5 bioMérieux India — Revenue, Strategy, Key Products
  • 8.6 Tulip Diagnostics (P) Ltd — Revenue, Strategy, Key Products
  • 8.7 J. Mitra & Co. Pvt. Ltd. — Revenue, Strategy, Key Products
  • 8.8 Transasia Bio-Medicals Ltd — Revenue, Strategy, Key Products
  • 8.9 Mylab Discovery Solutions Pvt. Ltd. — Revenue, Strategy, Key Products
  • 8.10 Meril Diagnostics Pvt. Ltd. — Revenue, Strategy, Key Products
09Competitive Landscape
  • 9.1 Market Concentration & Competitive Intensity
  • 9.2 Market Share Analysis (2024) — Multinational vs. Domestic Players
  • 9.3 Competitive Positioning Matrix — Price Point vs. Technology Sophistication
  • 9.4 Recent Developments: M&A, Partnerships & Product Launches (2023-2025)
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitute Products
  • 10.5 Competitive Rivalry Intensity
11PESTLE Analysis
  • 11.1 Political Factors
  • 11.2 Economic Factors
  • 11.3 Social & Demographic Factors
  • 11.4 Technological Factors
  • 11.5 Legal & Regulatory Factors
  • 11.6 Environmental Factors
12SWOT Analysis
  • 12.1 Market-Level Strengths
  • 12.2 Market-Level Weaknesses
  • 12.3 Strategic Opportunities
  • 12.4 External Threats
13Future Trends & Outlook
  • 13.1 Integration of Artificial Intelligence and Machine Learning in IVD Platforms for Automated Result Interpretation
  • 13.2 Miniaturised Lab-on-Chip and Microfluidic PoC Devices Targeting India's Rural Last-Mile Diagnostic Gap
  • 13.3 'Make in India' Driven Domestic Manufacturing Expansion — Shifting from Import Dependency to Export-Ready IVD Production
  • 13.4 Long-Term Market Outlook (2033-2035)
  • 13.5 Investment & M&A Activity Outlook

Frequently asked questions

What is the size of the India Point-of-Care Testing Devices and In-Vitro Diagnostics market?
The India PoC Testing Devices and IVD market was valued at approximately USD 3.2 billion in 2024. It is projected to reach approximately USD 6.8 billion by 2032, expanding at a CAGR of around 9.8% over the forecast period 2025-2032. In volume terms, total test throughput across PoC and IVD platforms exceeded 4,500 million dosage units in 2024, driven by high infectious disease screening volumes and growing chronic disease monitoring demand.
What is the CAGR of the India Point-of-Care Testing Devices and In-Vitro Diagnostics market?
The India PoC Testing and IVD market is forecast to grow at a CAGR of approximately 9.8% between 2025 and 2032. This rate is underpinned by government-driven diagnostic access programmes, rising non-communicable disease prevalence, and accelerating adoption of molecular and rapid diagnostic technologies across hospital, laboratory, and primary care settings.
What is driving growth in the India Point-of-Care Testing Devices and In-Vitro Diagnostics market?
Three primary forces are driving market expansion. First, the Ayushman Bharat PM-JAY scheme is funnelling an estimated 500 million previously uninsured beneficiaries into the formal healthcare system, creating structured demand for subsidised diagnostic testing. Second, the National Tuberculosis Elimination Programme's mandate for molecular PoC testing — specifically CBNAAT and TrueNat platforms — at district and sub-district hospitals has generated significant volume for molecular IVD suppliers. Third, India's diabetic population of over 100 million, combined with rising urban cardiovascular disease rates, is sustaining consistent annual demand growth for glucose monitoring, HbA1c, and cardiac marker PoC devices.
Who are the leading companies in the India Point-of-Care Testing Devices and In-Vitro Diagnostics market?
The market is served by a combination of multinational corporations and established domestic manufacturers. Abbott India Limited and Siemens Healthineers India command strong positions in immunoassay and clinical chemistry platforms. Roche Diagnostics India leads in molecular diagnostics and high-complexity IVD systems. On the domestic side, Transasia Bio-Medicals, J. Mitra & Co., and Tulip Diagnostics have built substantial market presence through affordable reagent kits and analysers tailored to Indian laboratory budgets. Mylab Discovery Solutions gained prominence through COVID-19 molecular test development and continues to expand its PoC portfolio.
Which region dominates the India Point-of-Care Testing Devices and In-Vitro Diagnostics market?
West India — led by Maharashtra — holds the largest revenue share within India, accounting for approximately 28% of the national market in 2024. This dominance reflects Mumbai and Pune's concentration of multi-specialty hospital networks, independent chain laboratories such as Dr. Lal PathLabs and Metropolis, and the presence of pharmaceutical and diagnostics manufacturing clusters. South India follows closely, with Karnataka and Tamil Nadu demonstrating above-average growth rates driven by expanding private healthcare infrastructure and medtech manufacturing activity centred on Bengaluru.
What segments are covered in this report?
The report covers the market across two primary segmentation axes. By product type, it analyses Rapid Diagnostic Tests and lateral flow assays, molecular diagnostics platforms (PCR, NAAT, isothermal amplification), glucose monitoring devices, immunoassay analysers and reagents, haematology and coagulation analysers, and urinalysis and clinical chemistry PoC strips. By application, the report covers infectious disease diagnostics (TB, malaria, dengue, HIV, COVID-19), diabetes and HbA1c monitoring, cardiac markers and acute care, women's health and maternal screening, oncology tumour marker testing, and drug-of-abuse testing.
What is the forecast period covered in this report?
This report covers a forecast period from 2025 to 2032, with 2024 as the base year. Historical data is provided from 2019 to 2024 to contextualise pre- and post-pandemic market dynamics. All forecasts are presented in USD billion for value and million dosage units for volume, with scenario analysis across base, bull, and bear cases.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from 1 195,00 $US
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.